Skip to content

Repeatability and Reproducibility of Cirrus HD-OCT Measurements of Illumination Areas Under the Retinal Pigment Epithelium

Repeatability and Reproducibility of Cirrus HD-OCT Measurements of Illumination Areas Under the Retinal Pigment Epithelium

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01890187
Enrollment
85
Registered
2013-07-01
Start date
2010-11-30
Completion date
2011-02-28
Last updated
2013-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Dry AMD With Geographic Atrophy

Brief summary

The objective of this study is to determine the repeatability and reproducibility of the Cirrus HD-OCT measurement of illumination areas under the retinal pigment epithelium (RPE).

Detailed description

This is a prospective, single site study. Ocular history and examination will be conducted on consented subjects to determine further participation in the study. The study will be divided into two phases. In Phase 1, the inter-device variability of Cirrus HD-OCT measurements of illumination areas under the RPE will be determined. In Phase 2, the inter-operator variability of Cirrus HD-OCT measurements of illumination areas under the RPE will be determined. In each of these phases, the Macular Cube 200 x 200 scan and the Macular Cube 512 x 128 scan will be evaluated.

Interventions

None listed

Sponsors

DataMed Devices Inc.
CollaboratorINDUSTRY
Carl Zeiss Meditec, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Males or females 50 years of age and older diagnosed to have advanced dry AMD with geographic atrophy. * Geographic atrophy lesions should: * Not be greater than 5 mm at the widest diameter. The entire lesion(s) should fit into the 6x6 mm scan area of the Cirrus HD-OCT. * Not be smaller than 1.25 mm2. * Not be confluent with peri-papillary atrophy. * Not be combined with other lesions such as CNV. * Able and willing to make the required study visits. * Able and willing to give consent and follow study instructions.

Exclusion criteria

* History of retinal surgery, laser photocoagulation, and/or radiation therapy to the eye. * Evidence of other retinal diseases of the eye, including wet AMD, diabetic retinopathy, diabetic macular edema, or significant vitreomacular traction. * Thick media opacity or inability to fixate that precludes obtaining acceptable scans. * Concomitant use of hydrochloroquine or chloroquine. * Unable to make the required study visits. * Unable to give consent or follow study instructions.

Design outcomes

Primary

MeasureTime frame
Coefficient of variation for area of increased illumination under the RPE (mm^2)Single visit observation

Secondary

MeasureTime frame
Coefficient of variation of the closest distance to foveaSingle visit observation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026